Effectiveness and quality analysis of methods in studies for the treatment of COVID-19
Tóm tắt
COVID-19 has spread and continues to spread rapidly across the world. There is still no approved and effective treatment for the disease. Several drugs are being administered empirically to patients, based on results from studies with limited methodologies. There is an urgent need for systematic reviews to support decision makers and the development of guidelines. The purpose of this paper was to conduct a systematic review of drug studies carried out worldwide for COVID-19, verifying the effectiveness and methodological quality. The search for relevant articles was performed in the Cochrane Central, MEDLINE, and Embase databases. The terms and combinations used for the search were ((coronavirus OR “2019-nCoV” OR 2019nCoV OR nCoV2019 OR “nCoV-2019” OR “COVID-19” OR COVID19 OR “HCoV-19” OR HCoV19 OR CoV OR “2019 novel*” OR Ncov OR “n-cov” OR “SARS-CoV-2” OR “SARSCoV-2” OR “SARSCoV2” OR “SARSCoV2” OR SARSCov19 OR “SARS-Cov19” OR “SARS-Cov-19”) OR “severe acute respiratory syndrome*” OR ((corona* OR corono*) AND (virus* OR viral* OR virinae*)) AND ((treatment) OR (medication) OR (symptoms)) AND (drugs)). The review process of the articles was carried out independently by four reviewers using the PRISMA-P method. As a result, a total of 30 articles were selected, which addressed the study of one or more medications for severe cases of COVID-19, which were hydroxychloroquine (or chloroquine) and azithromycin, lopinavir/ritonavir, lopinavir/ritonavir, arbidol, and Shufeng Jiedu Capsule, Combinations: remdesivir/lopinavir/homoharringtonine/emetine, remdesivir, interferon, lopinavir and ritonavir, thalidomide/methylprednisolone, tocilizumab, antimicrobial therapy. Despite efforts and studies, research does not provide evidence for the use of any drug to treat COVID-19, as the effects, safety, and efficacy are still uncertain. Thus, there is a need for systematic reviews to monitor, synthesize, and update the literature data on the subject, generating reliable evidence for decision makers. COVID-19 should be monitored and the need to develop effective drugs and vaccines to prevent disease progression must be reinforced.
Tài liệu tham khảo
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. Trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–99. https://doi.org/10.1056/NEJMoa2001282.
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19): StatPearls Publishing; 2020. PMid:32150360
Chen C, Qi F, Shi K, Li Y, Li J, Chen Y, Pan J, Zhou T, Lin X, Zhang J, Luo Y, Li X, Xia J. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 pneumonia. Preprints; 2020.
Choy KT, Wong AYL, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PPH, Huang X, Peiris M, Yen HL. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir Res 2020;178. PMid:32251767. https://doi.org/10.1016/j.antiviral.2020.104786, 104786.
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020;55. PMid:32145363. https://doi.org/10.1016/j.ijantimicag.2020.105932, 105932.
Contini C, Nuzzo M Di, Barp N, Bonazza A, de Giorgio R, Tognon M, Rubino S. The novel zoonotic COVID-19 pandemic: an expected global health concern. J Infect Dev Ctries 2020;14:254–264. PMid:32235085. https://doi.org/10.3855/jidc.12671.
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020. PMid:32173110. https://doi.org/10.1016/j.jcrc.2020.03.005, 57, 279, 283.
Das S, Bhowmick S, Tiwari S, Sen S. An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19). Clin Drug Investig. 2020;40:591–601. https://doi.org/10.1007/s40261-020-00927-1.
Deretic V, Timmins GS. BioRxiv: Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells; 2020.
van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564–7. https://doi.org/10.1056/NEJMc2004973.
Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents 2020. PMid:32251731. https://doi.org/10.1016/j.ijantimicag.2020.105960, 55, 105960.
Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72–3.
Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain J-M, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949. PMid:32205204. https://doi.org/10.1016/j.ijantimicag.2020.105949, 105949.
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020:NEJMoa2012410. https://doi.org/10.1056/NEJMoa2012410.
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox LA, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;382:929–936. PMid:32004427. https://doi.org/10.1056/NEJMoa2001191.
Hu BS, Gong JH, Sun J, Zhou JP. Exploring the epidemic transmission network of SARS in-out flow in mainland China. Chin Sci Bull. 2013;58:1818–31. https://doi.org/10.1007/s11434-012-5501-8.
Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:819–24. https://doi.org/10.1001/jamacardio.2020.1096.
Juul S, Nielsen N, Bentzer P, Veroniki AA, Thabane L, Linder A, et al. Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (the LIVING project). Syst Rev. 2020;9:108. https://doi.org/10.1186/s13643-020-01371-0.
Kupferschmidt K, Cohen J. Race find COVID-19 treatments accelerates. 2020
Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect 2020;9:687–690. PMid:32208840. https://doi.org/10.1080/22221751.2020.1741327.
Lim J, Jeon S, Shin HY, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020.
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020a;6:315–31. https://doi.org/10.1021/acscentsci.0c00272.
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020b;6:16. https://doi.org/10.1038/s41421-020-0156-0.
Liu L, Gao J. Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China. MedRxiv. 2020:2020.02.20.20025536. https://doi.org/10.1101/2020.02.20.20025536.
Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. Can Med Assoc J. 2020c;192:E734 LP–E744. https://doi.org/10.1503/cmaj.200647.
Madhav N, Oppenheim B, Gallivan M, Mulembakani P, Rubin E, Wolfe N. Pandemics: Risks, Impacts, and Mitigation. Dis. Control Priorities, Third Ed. (Volume 9) Improv. Heal. Reducing Poverty, The World Bank; 2017, p. 315–45. PMid:30212163. https://doi.org/10.1596/978-1-4648-0527-1_ch17.
Meo SA, Alhowikan AM, Khlaiwi TAL, Meo IM, Halepoto DM, Iqbal M, Usmani AM, Hajjar W, Ahmed N. Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24:2012–2019. PMid:32141570. https://doi.org/10.26355/eurrev_202002_20379.
Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold HS. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020. PMid:32356863. https://doi.org/10.1001/jamacardio.2020.1834, 5, 1036, 1041.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Estarli M, Barrera ESA, Martínez-Rodríguez R, Baladia E, Agüero SD, Camacho S, Buhring K, Herrero-López A, Gil-González DM, Altman DG, Booth A, Chan AW, Chang S, Clifford T, Dickersin K, Egger M, Gøtzsche PC, Grimshaw JM, Groves T, Helfand M, Higgins J, Lasserson T, Lau J, Lohr K, Mc Gowan J, Mulrow C, Norton M, Page M, Sampson M, Schünemann H, Simera I, Summerskill W, Tetzlaff J, Trikalinos TA, Tovey D, Turner L, Whitlock E. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Rev Esp Nutr Humana y Diet. 2016;20:148–160. PMid:25554246. https://doi.org/10.1186/2046-4053-4-1.
OPAS/OMS Brasil. Folha informativa – COVID-19 (doença causada pelo novo coronavírus). 2020. [cited 2020 May 18]. Available from: https://www.paho.org/bra/index.php?option=com_content&view=article&id=6101:covid19&Itemid=875.
Paudel S, Dangal G, Chalise A, Bhandari TR, Dangal O. The coronavirus pandemic: What does the evidence show? J Nepal Health Res Counc. 2020;18:1–9. PMid:32335585. https://doi.org/10.33314/jnhrc.v18i1.2596.
Reina J. Remdesivir, the antiviral hope against SARS-CoV-2. Rev Esp Quimioter Publ Of La Soc Esp Quimioter. 2020;33:176–9.
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020. PMid:32392282. https://doi.org/10.1001/jama.2020.8630, 323, 2493, 2502.
Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection. Albany NY: Aging; 2020.
Scuccimarri R, Sutton E, Fitzcharles M-A. Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic. J Rheumatol. 2020;47:783–6.
Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19. Cochrane Database Syst Rev. 2020. https://doi.org/10.1002/14651858.CD013587.
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. https://doi.org/10.1136/bmj.m1849.
Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershan AA, Kamal MA, et al. Therapeutic management of patients with COVID-19: a systematic review. Infect Prev Pract. 2020;2:100061. https://doi.org/10.1016/j.infpip.2020.100061.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020a;30:269–271. PMid:32020029. https://doi.org/10.1038/s41422-020-0282-0.
Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel Coronavírus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020b;14:64–8. https://doi.org/10.5582/bst.2020.01030.
Weston S, Haupt R, Logue J, Matthews K, Frieman M. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. BioRxiv. 2020:2020.03.25.008482. https://doi.org/10.1101/2020.03.25.008482.
de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020;117:6771–6776. PMid:32054787. https://doi.org/10.1073/pnas.1922083117.
World Health Organization. Infection prevention and control of epidemic-and pandemic-prone acute respiratory infections in health care WHO Guidelines. WHO. 2014. [cited 2020 May 18]. Available from: https://www.who.int/publications/i/item/infection-prevention-and-control-of-epidemic-and-pandemic-prone-acute-respiratory-infections-in-health-care.
World Health Organization (WHO). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020. [cited 2020 May 18]. Available from: https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19).
Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. In: Effective treatment of severe COVID-19 patients with tocilizumab; 2020.
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. PMid:32150618. https://doi.org/10.1093/cid/ciaa237, 71, 732, 739.
Yeh SH, Wang HY, Tsai CY, Kao CL, Yang JY, Liu HW, et al. Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution. Proc Natl Acad Sci U S A. 2004;101:2542–7. https://doi.org/10.1073/pnas.0307904100.
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020:105955. PMid:32234468. https://doi.org/10.1016/j.ijantimicag.2020.105955, 105955.